Last Updated on June 25, 2026 by Dr. Bhagat
JOURNAL METRICS·Updated June 2026
JCI Insight Impact Factor 2025 is 6.8 (Q1, Medicine, Research & Experimental, SCIE). Published by American Society for Clinical Investigation. Median first decision: ~10-14 days. Acceptance rate ~20-25%. Full JCR data, desk rejection analysis, and submission guide.
JCI Insight is a peer-reviewed open-access medical journal published by the American Society for Clinical Investigation (ASCI). Launched in 2016 as a companion to the Journal of Clinical Investigation, JCI Insight publishes well-executed, high-quality research across all biomedical specialties with an emphasis on clinical and translational investigation.
Key Takeaways
- Impact Factor (2025): 6.8 — strong clinical and translational focus
- JCR Quartile: Q1 (Medicine, Research & Experimental)
- Publisher: American Society for Clinical Investigation (ASCI)
- ISSN: 2379-3708 (online)
- Frequency: Continuous publication (biweekly issues)
- Open Access: Fully open access (APC ~$3,000)
- Acceptance Rate: Approximately 20-25%
OVERVIEWJCI Insight Journal Overview
JCI Insight publishes original research articles that report mechanistically driven clinical and preclinical investigations. The journal covers all areas of biomedicine including immunology, endocrinology, gastroenterology, hematology, neuroscience, oncology, cardiovascular medicine, nephrology, pulmonology, rheumatology, and genetics. The journal prioritizes studies that provide clear mechanistic insight into human disease or demonstrate translational relevance to clinical medicine.
IMPACT FACTORJCI Insight Impact Factor 2025
| Metric | Value |
|---|---|
| 2025 Impact Factor | 6.8 |
| JCR Quartile | Q1 (Medicine, Research & Experimental) |
| 5-Year Impact Factor | ~7.2 |
| Total Citations | ~45,000+ |
JCI Insight holds a 2025 impact factor of 6.8 in the Medicine, Research & Experimental category, ranking Q1. The journal has established itself as a respected venue for clinical and translational research since its launch in 2016.
INDEXINGIndexing and Abstracting
JCI Insight is indexed in Science Citation Index Expanded (SCIE), PubMed/MEDLINE, PubMed Central (PMC), Scopus, and Embase. The journal is deposited in PMC immediately upon publication, ensuring full open-access discoverability.
SCOPUSScopus CiteScore
JCI Insight has a Scopus CiteScore of approximately 11.2, placing it in the 90th percentile of medical research journals. Articles receive an average of 6-8 citations within the first two years of publication.
SUBJECTSubject Areas
JCI Insight publishes across all biomedical specialties, with particular emphasis on:
- Immunology and Autoimmune Diseases
- Endocrinology and Metabolism
- Gastroenterology and Hepatology
- Hematology
- Neuroscience and Neurology
- Oncology and Cancer Biology
- Cardiovascular Medicine
- Nephrology and Hypertension
- Pulmonology and Critical Care
- Rheumatology
- Genetics and Genomics
- Infectious Diseases
- Vascular Biology
PUBLISHERPublisher Information
JCI Insight is published by the American Society for Clinical Investigation (ASCI), one of the oldest and most respected medical honor societies in the United States. Founded in 1908, ASCI is dedicated to the advancement of research that extends understanding and improves the treatment of human diseases. The society’s membership is limited to 3,000 physician-scientists elected based on outstanding contributions to clinical research.
CONTACTContact and Editorial Office
| Detail | Information |
|---|---|
| Publisher | American Society for Clinical Investigation |
| Headquarters | Ann Arbor, MI, USA |
| Editorial Office | insight@the-jci.org |
| Submission System | https://www.jci.org/insight-submit |
| Website | https://insight.jci.org |
OPEN ACCESSOpen Access Policy
JCI Insight is a fully open-access journal. All articles are published under a Creative Commons Attribution license and are freely available immediately upon publication. Authors pay an article processing charge (APC) of approximately $3,000 USD. The journal does not have subscription fees; revenue is derived entirely from APCs. ASCI members receive discounted APCs.
GUIDELINESAuthor Guidelines
JCI Insight publishes Research Articles, Clinical Medicine Reports, Brief Reports, Reviews, and Commentaries. Research Articles present original findings with clear mechanistic insight. Clinical Medicine Reports highlight clinically relevant observations. Brief Reports present concise, high-impact findings. Manuscripts are submitted through the ASCI Editorial Manager system. All human studies must include appropriate ethics approvals and informed consent.
METRICSAdditional Metrics and Rankings
| Metric | Value |
|---|---|
| Impact Factor (2025) | 6.8 |
| JCR Ranking | Q1 (Medicine, Research & Experimental) |
| Scopus CiteScore | ~11.2 |
| Article Influence Score | ~2.5 |
| Acceptance Rate | ~20-25% |
| Time to First Decision | ~10-14 days |
| ISSN | 2379-3708 |
| Frequency | Continuous (biweekly) |
| First Published | 2016 |
| Publisher | American Society for Clinical Investigation |
SUBMISSIONSubmission and Review Process
Manuscripts submitted to JCI Insight undergo initial editorial screening to assess suitability and novelty. Articles that pass screening are sent for peer review by 2-3 expert referees. The journal emphasizes rigor of methodology, clarity of mechanistic insight, and translational relevance. Authors typically receive a first decision within 10-14 days. Revision requests are common, and most accepted articles undergo at least one round of revision.
HISTORYHistory and Background
JCI Insight was launched in 2016 under the editorship of Dr. Howard Rockman, building on the century-long reputation of the Journal of Clinical Investigation (founded 1924). The new journal was created to meet the growing demand for a high-quality, fully open-access venue for clinical and translational research. Since its inception, JCI Insight has published over 4,000 articles and has grown to publish approximately 600 articles annually.
ETHICSEthics and Policies
JCI Insight follows COPE guidelines and ASCI ethical standards. The journal requires disclosure of all competing interests, data availability statements, and complete methods descriptions. Human studies require IRB/ethics approval and informed consent documentation. Animal studies require IACUC approval. JCI Insight uses Crossref Similarity Check and screens all images for manipulation. The journal endorses the ICMJE authorship criteria.
CITATIONCitation Trends and Analysis
Despite its relatively recent launch, JCI Insight has established a strong citation record. The journal’s h5-index is approximately 92. Highly cited articles accumulate 100-300+ citations within five years. The open-access model contributes to broad citation patterns across clinical and basic science literature. The journal’s citation trajectory continues to grow year over year.
FAQFrequently Asked Questions
What is the current Impact Factor of JCI Insight?
The 2025 Impact Factor of JCI Insight is 6.8, ranking Q1 in Medicine, Research & Experimental.
Is JCI Insight a Q1 journal?
Yes, JCI Insight is a Q1 journal in the Medicine, Research & Experimental category.
Who publishes JCI Insight?
JCI Insight is published by the American Society for Clinical Investigation (ASCI).
Is JCI Insight fully open access?
Yes, JCI Insight is fully open access. All articles are freely available immediately upon publication under a CC BY license.
What is the acceptance rate for JCI Insight?
The acceptance rate is approximately 20-25%.
How long does the review process take?
Authors receive a first decision within 10-14 days of submission.
What is the APC for JCI Insight?
The article processing charge is approximately $3,000 USD, with discounts for ASCI members.
What types of articles does JCI Insight publish?
JCI Insight publishes Research Articles, Clinical Medicine Reports, Brief Reports, Reviews, and Commentaries.
